Choose HA†
Prescribing Information   |  OAKneePainRelief.com
3.0-header-iStock-912135124

Clinically proven efficacy and safety

Contact a Rep

Choose GELSYN-3 for proven outcomes9

GELSYN-3 has efficacy equivalent to a high-molecular-weight hyaluronic acid comparator:

  • A 3-injection series of GELSYN-3 (0.8% highly purified, hyaluronic acid of biofermentation origin) or Synvisc® (0.8% hylan G-F 20)
  • Patients (N=380) were observed for a period of 26 weeks
  • Primary outcome measure: WOMAC pain score at 26 weeks

Synvisc is a registered trademark of Genzyme Biosurgery.

Pain Reduction Tolerability Percentage

 

GELSYN-3 also demonstrated improvements in knee function, stiffness, and global pain scores.

2.1-middlesection-iStock-1081493552

GELSYN-3 performed as well as Synvisc in terms of effectiveness and safety, providing patients with long-lasting, clinically relevant pain relief.9

See GELSYN-3 Safety Information

DUROLANE, GELSYN-3 and SUPARTZ FX are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g., acetaminophen. Risks include general knee pain and pain at the injection site.

View Use and Important Safety Information at: DUROLANE.com, GELSYN3.com, and SUPARTZFX.COM

Summary of Indications for Use:
DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen.

Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site.

DUROLANE has not been tested in pregnant or lactating women, or children.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

Summary of Indications for Use:
GELSYN-3 is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen). Do not administer to patients with known hypersensitivity (allergy) to sodium hyaluronate preparations. Do not inject GELSYN-3 into the knees of patients having knee joint infections or skin diseases or infections in the area of the injection site.

GELSYN-3 is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.

Summary of Indications for Use:
SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen. You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site.

Full prescribing information can be found in product labeling, or by contacting Bioventus Customer Service at 800-836-4080.